Year Founded
1993
Ownership
Public
Employees
~500
Therapeutic Areas
Immunology
Stage
Commercial
Modalities
Small molecule

Aurinia Pharmaceuticals General Information

Lead product LUPKYNIS (voclosporin) approved and commercialized for lupus nephritis. Pipeline includes AUR200 and AUR300 in preclinical development for autoimmune diseases.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Rockville, Maryland
United States

Drug Pipeline

voclosporin
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Aurinia Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

Otsuka Pharmaceutical

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Aurinia Pharmaceuticals Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Aurinia Pharmaceuticals's complete valuation and funding history, request access »

Aurinia Pharmaceuticals Licensing Deals

AssetLicenseeDateTherapeutic Area
lupkynisOtsukaDec 1, 2020Immunology
lupkynisOtsukaN/AImmunology
lupkynisOtsukaDec 17, 2020Immunology
LUPKYNISOtsuka PharmaceuticalN/AImmunology
lupkynisOtsukaJan 1, 2020Immunology
rencofilstatCiclofilinFeb 14, 2014Liver
voclosporinOtsukaDec 1, 2020Immunology
You're viewing 2 of 7 licensing deals. Get the full list »

Aurinia Pharmaceuticals Investors

Franklin Resources Inc.
Investor Type: Venture Capital
Holding: Minority
FMR LLC
Investor Type: Venture Capital
Holding: Minority